Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

165 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-01

Study Completion Date

2018-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

NCT04704947

Beta Blocker Toxicity

RECRUITING PHASE3

Atenolol for the Prevention of Osteoporosis (APO)

NCT04905277

Healthy

ACTIVE_NOT_RECRUITING PHASE2

Alendronate and/or Parathyroid Hormone for Osteoporosis

NCT00000400

Osteoporosis

COMPLETED PHASE2

Secondary Prevention of Osteoporosis

NCT00421343

Osteoporosis

COMPLETED PHASE3

Anabolic Therapy in Postmenopausal Osteoporosis

NCT05010590

Postmenopausal Osteoporosis

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In postmenopausal women, who have increased sympathetic outflow, to test the hypothesis that treatment with low doses of a non-selective β-blocker (propranolol) will increase serum markers of bone formation and reduce markers of bone resorption (Aim 1a); and using increasingly β1-AR (adrenergic receptor) selective blockers (atenolol and nebivolol), to better define the β-adrenergic receptor selectivity (β1 versus β2) in the regulation of bone turnover by sympathetic outflow in humans.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis, Age-Related

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Intervention Type DRUG

beta blocker

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atenolol

beta blocker

Intervention Type DRUG

Nebivolol

beta blocker

Intervention Type DRUG

Propranolol

beta blocker

Intervention Type DRUG

placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* at least 5 yrs since their last menses
* Follicle Stimulating Hormone (FSH) \> 20 IU/L

Exclusion Criteria

* Abnormality in any of the screening laboratory studies
* Presence of significant liver or renal disease
* Malignancy (including myeloma)
* Malabsorption
* Diabetes
* Hypoparathyroidism
* Hyperparathyroidism
* Acromegaly
* Cushing's syndrome
* Hypopituitarism
* Severe chronic obstructive pulmonary disease
* Undergoing treatment with any medications that affect bone turnover, including the following:
* adrenocorticosteroids (\> 3 months at any time or \> 10 days within the previous yr)
* anticonvulsant therapy (within the previous year)
* pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal)
* calcium supplementation of \> 1200 mg/d (within the preceding 3 months)
* bisphosphonates (within the past 3 yrs)
* denosumab
* estrogen (E) therapy within the past year
* treatment with a selective E receptor modulator within the past year
* teriparatide within the past yr
* anti-hypertensive therapy

* Clinical history of osteoporotic fracture (vertebral, hip, or distal forearm
* Recent (within the past 6 months) fracture
* Serum 25-hydroxyvitamin D levels of \< 20 ng/ml
* Resting blood pressure \>140/90 mm Hg or those with hypotension (systolic blood pressure \<110 mm Hg), heart rate \< 60 bpm
* History of asthma

Minimum Eligible Age

50 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes